Effect of diet and exercise program to improve polycystic ovary syndrome (PCOS)

INTERVENTION: Experimental group: Diet and exercise program Diet plan: at the beginning of study a check list prepared for each individual and weekly regimen recommended separately based on feeding patterns and individual facilities. The method of regimen calculation based on total energy for each individual (TEE). We set the countable energy for reducing weight 1000 grams per week. Reduced the amount of energy and some energy into the physical activity to lose weight fraction are obtained. The combination of energy, including 40% carbohydrate, 30% fat (less than 8% saturated fatty acids was) and 30% protein is high physiological value. Fitness program: exercise sessions that included 24 meeting which duration per session was variable according to the program. For improving aerobic energy system and strengthen cardiovascular system a series exercises (slow jogging) will be used. At the beginning of the first practice sessions will be used slow intensity aerobic exercise. The first training se For controls group: The standard drugs Diane: from fifth Day of cycle for 21 days every night, once a day Spironolactone: 25 mg twice a day Intervention 1: Experimental group: Diet and exercise program Diet plan: at the beginning of study a check list prepared for each individual and weekly regimen recommended separately based on feeding patterns and individual facilities. The method of regimen calculation based on total energy for each individual (TEE). We set the countable energy for reducing weight 1000 grams per week. Reduced the amount of energy and some energy into the physical activity to lose weight fraction are obtained. The combination of energy, including 40% carbohydrate, 30% fat (less than 8% saturated fatty acids was) and 30% protein is high physiological value. Fitness program: exercise sessions that included 24 meeting which duration per session was variable according to the program. For improving aerobic energy system and strengthen cardiovascular system a series exercises (slow jogging) will be used. At the beginning of the first practice sessions will be used slow intensity aerobic exercise. The first training sessions with 5 minutes of times, and 50 percent of maximum heart rate of cholera in the form alternating between resting half the time repeating the exercise. In each session we were trying to follow the principle of overload for improving cardiovascular efficiency. In higher stages (after the fifth session) of the repetition of exercises with some 60 percent of maximum heart rate is achieved. Of the ninth session, training intensity reaches to 70 percent of maximum heart rate and in last sessions with 80 percent maximum heart rate do their exercise. In each session, subjects in the first 10 minutes to warm the body and also the final 10 minutes of cooling down exercises and return to the initial state. Intervention 2: For controls group: The standard drugs Diane: from fifth Day of cycle for 21 days every night, once a day Spironolactone: 25 mg twice a day. Lifestyle Treatment ‐ Drugs CONDITION: Endocrine, nutritional and metabolic diseases(E00‐E90) polycystic ovary syndrome. ; Endocrine, nutritional and metabolic diseases(E00‐E90) INCLUSION CRITERIA: INCLUSION CRITERIA: Exclusion criteria: PRIMARY OUTCOME: Body mass index(BMI). Timepoint: Before intervention ‐ three months after intervention. Method of measurement: By measuring the height (m) and weight (kg). Hirsutism. Timepoint: Before intervention ‐ three months after intervention. Method of measurement: Using Friedman and Galway scale. Oligomenorrhea. Timepoint: Before intervention ‐ three months after intervention. Method of measurement: Considering the menstrual cycle (irregular bleeding episodes with intervals of more than 35 days). Ovary status. Timepoint: Before intervention ‐ three months after intervention. Method of measurement: using abdominal ultrasound. Serum Dehydroepiandrosterone Sulphate (DHEAS). Timepoint: Before intervention ‐ three months after intervention. Method of measurement: Serological test with Electro Komolomynsans method with using of the company's ROCHE kits. Serum sex hormone binding globulin (SHBG). Timepoint: Before intervention ‐ three months after intervention. Method of measurement: Serological test with Electro Komolomynsans method with using of the company's ROCHE kits. Serum testosterone(total & free). Timepoint: Before intervention ‐ three months after intervention. Method of measurement: Serological test with Electro Komolomynsans method with using of the company's ROCHE kits. SECONDARY OUTCOME: Serum FSH. Timepoint: Before intervention ‐ three months after intervention. Method of measurement: Serological test with Electro Komolomynsans method with using of the company's ROCHE kits. Serum LH. Timepoint: Before intervention ‐ three months after intervention. Method of measurement: Serological test with Electro Komolomynsans method with using of the company's ROCHE kits. Serum Progestron. Timepoint: Before intervention ‐ three months after intervention. Method of measurement: Serological test with Electro Komolomynsans method with using of the company's ROCHE kits. Serum prolactin. Timepoint: Before intervention ‐ three months after intervention. Method of measurement: Serological test with Electro Komolomynsans method with using of the company's ROCHE kits. Serum stradiol. Timepoint: Before intervention ‐ three months after intervention. Method of measurement: Serological test with Electro Komolomynsans method with using of the company's ROCHE kits. Serum T3. Timepoint: Before intervention ‐ three months after intervention. Method of measurement: Serological test with Electro Komolomynsans method with using of the company's ROCHE kits. Serum T4. Timepoint: Before intervention ‐ three months after intervention. Method of measurement: Serological test with Electro Komolomynsans method with using of the company's ROCHE kits. Serum TSH. Timepoint: Before intervention ‐ three months after intervention. Method of measurement: Serological test with Electro Komolomynsans method with using of the company's ROCHE kits. 1‐ Participants have body mass index= 25 kg/ m2; 2‐ All Participants treat with same dose of oral contraceptives pill and spirnolacton; 3‐ All Participants have menstrual pattern as oligomenorrhea (irregular bleeding episodes with intervals occur more than 35 days); 4‐ All Participants have suffered some degree of hirsutism. 1‐ Use of any drug other than the standard drug for the treatment of polycystic ovary syndrome, which is the same for everyone. (Including drugs to treat infertility, diabetes, hormonal drugs, reduce appetite and etc); 2‐ Smoking; 3‐ Being in pregnancy and lactation period or pregnancy decision; 4‐ Having cardiovascular, renal, liver, respiratory diseases, diabetes, uncontrolled hypertension, malignancy or any other acute or chronic disease; 5‐ Prohibition of the exercise due to illness or any other cause according to physician order; 6‐ Participating in regular exercise before the start o